$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism

$vism Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000165495424001969 Filed on February 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$399.6K	$1.083M
YoY Change	-29.64%	102.88%
% of Gross Profit
Research & Development	$19.45K	$19.45K
YoY Change	-73.63%	-58.68%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$419.1K	$1.103M
YoY Change	-34.7%	89.79%
Operating Profit	-$419.1K	-$1.103M
YoY Change	-34.7%	89.79%
Interest Expense	$74.71K	$132.0K
YoY Change	268.68%	254.89%
% of Operating Profit
Other Income/Expense, Net	-$59.01K	-$105.7K
YoY Change	-34.69%	-24.81%
Pretax Income	-$478.1K	-$1.208M
YoY Change	-34.7%	67.47%
Income Tax
% Of Pretax Income
Net Earnings	-$478.1K	-$1.208M
YoY Change	-34.7%	67.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	105.8M shares	77.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.250K	$8.480K
YoY Change	-82.35%	-72.99%
Cash & Equivalents	$8.247K	$8.478K
Short-Term Investments
Other Short-Term Assets	$19.45K	$38.89K
YoY Change	11.14%	11.11%
Inventory
Prepaid Expenses	$19.45K	$38.89K
Receivables
Other Receivables
Total Short-Term Assets	$27.69K	$47.37K
YoY Change	-56.9%	-28.65%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$27.69K	$47.37K
Total Long-Term Assets	$0.00	$0.00
Total Assets	$27.69K	$47.37K
YoY Change	-56.9%	-28.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.063M	$1.019M
YoY Change	60.75%	58.38%
Accrued Expenses	$2.346M	$2.212M
YoY Change	44.4%	51.28%
Deferred Revenue
YoY Change
Short-Term Debt	$1.327M	$1.354M
YoY Change	-25.27%	-23.24%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.937M	$4.772M
YoY Change	14.4%	17.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.937M	$4.772M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$4.937M	$4.772M
YoY Change	14.4%	17.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.77M	-$62.15M
YoY Change	6.31%	6.57%
Common Stock	$12.65K	$9.652K
YoY Change	2162.61%	2325.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.910M	-$4.725M
YoY Change
Total Liabilities & Shareholders Equity	$27.69K	$47.37K
YoY Change	-56.9%	-28.65%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$478.1K	-$1.208M
YoY Change	-34.7%	67.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$100.3K	-$121.5K
YoY Change	-42.54%	9.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.1K	99.44K
YoY Change	-47.31%	-16.79%
NET CHANGE
Cash From Operating Activities	-100.3K	-121.5K
Cash From Investing Activities
Cash From Financing Activities	100.1K	99.44K
Net Change In Cash	-230.0	-22.06K
YoY Change	-101.5%	-350.11%
FREE CASH FLOW
Cash From Operating Activities	-$100.3K	-$121.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	48018	usd
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	38998249	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11348	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11348	shares
	vism	Incremental Common Shares Attributable To Common Stock Option IncrementalCommonSharesAttributableToCommonStockOption	2222	shares
CY2023	vism	Incremental Common Shares Attributable To Common Stock Option IncrementalCommonSharesAttributableToCommonStockOption	2222	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5114576	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5115207	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	87448375	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	50433146	shares
	vism	Annually Prepaid License Fee AnnuallyPrepaidLicenseFee	77850	usd
	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	38893	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	32689	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	33862	usd
CY2023Q4	vism	Fair Value Of Warrant FairValueOfWarrant	0	usd
CY2023Q2	vism	Fair Value Of Warrant FairValueOfWarrant	0	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	48018	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	80707	usd
CY2023Q4	vism	Derivative Liabilities Fair Value Assumptions Exercise Price DerivativeLiabilitiesFairValueAssumptionsExercisePrice	0.0082
CY2022Q4	vism	Derivative Liabilities Fair Value Assumptions Market Price DerivativeLiabilitiesFairValueAssumptionsMarketPrice	0.081
	vism	Derivative Liabilities Fair Value Assumptions Expected Volatility Rate DerivativeLiabilitiesFairValueAssumptionsExpectedVolatilityRate	2.6804	pure
	vism	Derivative Liabilities Fair Value Assumptions Risk Free Interest Rate DerivativeLiabilitiesFairValueAssumptionsRiskFreeInterestRate	0.0559	pure
	vism	Derivative Liabilities Fair Value Assumptions Expected Term DerivativeLiabilitiesFairValueAssumptionsExpectedTerm	P60M
	vism	Expected Dividend Rate ExpectedDividendRate	0	pure
	vism	Expected Dividend Rate ExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	80707	usd
	vism	Loss On Change In Fair Value Of Derivative Liabilities LossOnChangeInFairValueOfDerivativeLiabilities	-32689	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	48018	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	548041	usd
	vism	Conversion Of Accrued Interest ConversionOfAccruedInterest	-187805	usd
	vism	Interest Expense In Cash InterestExpenseInCash	7560	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	512542	usd
CY2023Q3	vism	Convertible Notes Payable1 ConvertibleNotesPayable1	774502	usd
CY2023Q2	vism	Convertible Notes Payable1 ConvertibleNotesPayable1	973576	usd
CY2023Q3	vism	Discount On Convertible Notes Payable DiscountOnConvertibleNotesPayable	-2437	usd
CY2023Q2	vism	Discount On Convertible Notes Payable DiscountOnConvertibleNotesPayable	0	usd
CY2023Q3	vism	Convertible Notes Payable To Related Parties Current ConvertibleNotesPayableToRelatedPartiesCurrent	772065	usd
CY2023Q2	vism	Convertible Notes Payable To Related Parties Current ConvertibleNotesPayableToRelatedPartiesCurrent	973576	usd
	vism	Convertible Notes Issued55 ConvertibleNotesIssued55	86717	usd
	vism	Discount Related To Convertible Notes Payable DiscountRelatedToConvertibleNotesPayable	-2437	usd
	vism	Conversion Of Convertible Notes Payable Into Common Stock ConversionOfConvertibleNotesPayableIntoCommonStock	-205724	usd
CY2023Q4	vism	Convertibles Notes Payable ConvertiblesNotesPayable	772065	usd
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	24246430	shares
	vism	Totalconvertible Notes Payable Principle Amount TotalconvertibleNotesPayablePrincipleAmount	205724	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	187805	usd
	vism	Total Convertible Notes Payable Conversion Expense TotalConvertibleNotesPayableConversionExpense	15750	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	409276	usd
	vism	Loss On Extinguishment Of Debt Related To Payoff Of Convertible Note LossOnExtinguishmentOfDebtRelatedToPayoffOfConvertibleNote	-12035	shares
CY2023Q3	vism	Loss On Extinguishment Of Debt Related To Payoff Of Convertible Note LossOnExtinguishmentOfDebtRelatedToPayoffOfConvertibleNote	-12035	shares
CY2023Q3	vism	Gain On Extinguishment Of Debt Amount GainOnExtinguishmentOfDebtAmount	-12035	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	484460	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96813626	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96501142	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	631	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5114576	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5114576	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.023
CY2023Q4	vism	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingNumber	5114576	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3M20D
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.023
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5114576	shares
CY2023Q4	vism	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice	0.023
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	11852000000	shares
CY2023Q4	us-gaap	Share Price SharePrice	20.25
	vism	Fair Value Of Shares FairValueOfShares	0.00
	vism	Options To Purchase Vested Shares OptionsToPurchaseVestedShares	2222	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
	vism	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2222	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	27.00
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	vism	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term Begining SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermBegining	P2Y3M29D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	27.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y3M29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M29D
CY2023Q4	vism	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2222	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	27.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y3M29D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7297475	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	35425000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.0169
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	42409999	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.022
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	312476	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.289
CY2023Q4	vism	Due To Officers Current DueToOfficersCurrent	139633	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1371879	usd
	vism	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.57
	dei	Entity Central Index Key EntityCentralIndexKey	0001082733
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37199647	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-25753
	dei	Entity Registrant Name EntityRegistrantName	VISIUM TECHNOLOGIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0449667
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4094 Majestic Lane
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 360
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fairfax
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22033
	dei	City Area Code CityAreaCode	703
	dei	Local Phone Number LocalPhoneNumber	273-0383
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105838642	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8478	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9982	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38893	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	47371	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	9982	usd
CY2023Q4	us-gaap	Assets Assets	47371	usd
CY2023Q2	us-gaap	Assets Assets	9982	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1019019	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	845502	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1699379	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1371879	usd
CY2023Q4	vism	Due From Officers Stockholders DueFromOfficersStockholders	139633	usd
CY2023Q2	vism	Due From Officers Stockholders DueFromOfficersStockholders	99578	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	512542	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	2437	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	772065	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	937576	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	48018	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80707	usd
CY2023Q4	vism	Notes Payable Net Of Discount NotesPayableNetOfDiscount	15872	usd
CY2023Q2	vism	Notes Payable Net Of Discount NotesPayableNetOfDiscount	26805	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	581628	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	380013	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4772284	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4263296	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96813626	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96501142	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29844713	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9652	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2987	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57400982	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55597779	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62150867	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59869400	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4724913	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4253314	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47371	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9982	usd
CY2023Q4	us-gaap	Revenues Revenues	0	usd
CY2022Q4	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1083168	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	533892	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1591308	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	893581	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19446	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47060	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47809	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101952	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1102614	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	580952	usd
	us-gaap	Operating Expenses OperatingExpenses	1639117	usd
	us-gaap	Operating Expenses OperatingExpenses	995533	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1102614	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-580952	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1639117	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-995533	usd
CY2023Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	93085	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-45233	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	32689	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-33862	usd
CY2023Q4	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	usd
CY2022Q4	vism	Derivative Liability Expense DerivativeLiabilityExpense	58139	usd
	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	usd
	vism	Derivative Liability Expense DerivativeLiabilityExpense	58139	usd
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-66765	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12035	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-504925	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	132014	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	37199	usd
	us-gaap	Interest Expense InterestExpense	178544	usd
	us-gaap	Interest Expense InterestExpense	166940	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105694	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-140571	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-157890	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-763866	usd
CY2023Q4	vism	Net Income Losses NetIncomeLosses	-1208308	usd
CY2022Q4	vism	Net Income Losses NetIncomeLosses	-721523	usd
	vism	Net Income Losses NetIncomeLosses	-1797007	usd
	vism	Net Income Losses NetIncomeLosses	-1759399	usd
CY2023Q4	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q4	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	484460	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1208308	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-721523	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2281467	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1759399	usd
CY2023Q4	vism	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.02
CY2022Q4	vism	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.22
	vism	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.04
CY2023Q4	vism	Weighted Average Number Of Diluted Shares Outstanding1 WeightedAverageNumberOfDilutedSharesOutstanding1	78899929	shares
CY2022Q4	vism	Weighted Average Number Of Diluted Shares Outstanding1 WeightedAverageNumberOfDilutedSharesOutstanding1	3271675	shares
	vism	Weighted Average Number Of Diluted Shares Outstanding1 WeightedAverageNumberOfDilutedSharesOutstanding1	57608052	shares
	vism	Weighted Average Number Of Diluted Shares Outstanding1 WeightedAverageNumberOfDilutedSharesOutstanding1	3085138	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4615834	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	258749	usd
CY2023Q4	vism	Shares Issued As Compensation To Employees Amount SharesIssuedAsCompensationToEmployeesAmount	85352	usd
CY2023Q4	vism	Shares Issued As Compensation To Directors And Officers Amount SharesIssuedAsCompensationToDirectorsAndOfficersAmount	457756	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	304234	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1208308	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4724913	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4253314	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	306100	usd
	vism	Shares Issued As Compensation To Employees Amount SharesIssuedAsCompensationToEmployeesAmount	89408	usd
	vism	Shares Issued As Compensation To Directors And Officers Amount SharesIssuedAsCompensationToDirectorsAndOfficersAmount	520624	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	409276	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1797007	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4724913	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3601480	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3100	usd
CY2022Q4	vism	Shares Issued As Compensation To Employees Amount SharesIssuedAsCompensationToEmployeesAmount	72850	usd
CY2022Q4	vism	Shares Issued As Compensation To Directors And Officers Amount SharesIssuedAsCompensationToDirectorsAndOfficersAmount	172604	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	77049	usd
CY2022Q4	vism	Shares Issued For Exercise Of Warrants Amount SharesIssuedForExerciseOfWarrantsAmount	0	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-721523	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3997400	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2793558	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18873	usd
	vism	Shares Issued As Compensation To Employees Amount SharesIssuedAsCompensationToEmployeesAmount	72850	usd
	vism	Shares Issued As Compensation To Directors And Officers Amount SharesIssuedAsCompensationToDirectorsAndOfficersAmount	199813	usd
	vism	Warrants Issued On Extinguishment Of Debt WarrantsIssuedOnExtinguishmentOfDebt	186972	usd
	vism	Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount	77049	usd
	vism	Shares Issued For Exercise Of Warrants Amount SharesIssuedForExerciseOfWarrantsAmount	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1759399	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3997400	usd
	us-gaap	Profit Loss ProfitLoss	1797007	usd
	us-gaap	Profit Loss ProfitLoss	1759399	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	916132	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	291536	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19896	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	94956	usd
	vism	Derivative Liability Expense DerivativeLiabilityExpense	0	usd
	vism	Derivative Liability Expense DerivativeLiabilityExpense	58139	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	32689	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-33862	usd
	vism	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	-12035	usd
	vism	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	-504925	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	173512	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	50467	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38893	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-152306	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-71981	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	327500	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	410434	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-267208	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-278099	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	235000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	44250	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	86717	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	105000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	51818	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	40055	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	67500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	265704	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	172500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1504	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-105599	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9982	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136990	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8478	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31391	usd
	us-gaap	Interest Paid Net InterestPaidNet	7560	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	vism	Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest	409276	usd
	vism	Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest	77049	usd
	vism	Warrants Issued On Extinguishment Of Debt WarrantsIssuedOnExtinguishmentOfDebt	0	usd
	vism	Warrants Issued On Extinguishment Of Debt WarrantsIssuedOnExtinguishmentOfDebt	186972	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1797007	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-267208	usd
CY2023Q4	vism	Working Capital Deficit WorkingCapitalDeficit	4724913	usd
	us-gaap	Fiscal Period FiscalPeriod	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fiscal year ends on June 30. References to fiscal year 2024, for example, refer to the fiscal year ending June 30, 2024.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reported period. Actual results will differ from those estimates. Included in these estimates are assumptions used in Cox, Ross & Rubinstein Binomial Tree stock-based compensation valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate and in the valuation allowance of deferred tax assets and derivative liability.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is subject to a concentration of credit risk from cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash account is held at a financial institution and is insured by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000. As of December 31, 2023 and June 30, 2023, the Company did not exceed these FDIC limits.</p>
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57608052	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6306120	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	24712177	shares
CY2022Q4	vism	Derivative Liabilities Fair Value Assumptions Exercise Price DerivativeLiabilitiesFairValueAssumptionsExercisePrice	0.058
CY2023Q4	vism	Derivative Liabilities Fair Value Assumptions Market Price DerivativeLiabilitiesFairValueAssumptionsMarketPrice	0.0169
	vism	Derivative Liabilities Fair Value Assumptions Expected Volatility Rate DerivativeLiabilitiesFairValueAssumptionsExpectedVolatilityRate	2.568	pure
	vism	Derivative Liabilities Fair Value Assumptions Risk Free Interest Rate DerivativeLiabilitiesFairValueAssumptionsRiskFreeInterestRate	0.0441	pure
	vism	Derivative Liabilities Fair Value Assumptions Expected Term DerivativeLiabilitiesFairValueAssumptionsExpectedTerm	P60M
	us-gaap	Liability For Future Policy Benefits Period Expense LiabilityForFuturePolicyBenefitsPeriodExpense	0	usd
	vism	Interest Expense Accrued InterestExpenseAccrued	159866	usd
CY2023Q4	vism	Convertibles Notes Payable ConvertiblesNotesPayable	772065	usd
CY2023Q2	vism	Convertibles Notes Payable ConvertiblesNotesPayable	973576	usd
	vism	Scheduleofconvertible Notes Payabletabletextblock ScheduleofconvertibleNotesPayabletabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">937,576</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes issued during the six months ended December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">86,717</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes repaid in cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(44,250 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Discount related to convertible notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,437 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of convertible notes payable into common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(205,724 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">772,065</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q2	vism	Convertibles Notes Payables ConvertiblesNotesPayables	937576	usd
	vism	Convertible Notes Repaid In Cash ConvertibleNotesRepaidInCash	-44250	usd
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	0.0169
	vism	Unvested Shares Issued For The Restricted Stock UnvestedSharesIssuedForTheRestrictedStock	312476	shares
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	504925	usd
	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	5048426	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5115207	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.025
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	vism	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Warrant ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceWarrant	10.395
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.023
	vism	Plan Terminates Period PlanTerminatesPeriod	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2023	vism	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2222	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2222	shares
	vism	Accrued Payrolldisclosuretextblock AccruedPayrolldisclosuretextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 10 - ACCRUED PAYROLL</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accrued payroll consist of the following at:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued Payroll - officers</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,042,362</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900,846</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued payroll - staff</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">657,017</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">471,033</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,699,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,371,879</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1699379	usd

Files In Submission

Name	View Source	Status
0001654954-24-001969-index-headers.html	Edgar Link	pending
0001654954-24-001969-index.html	Edgar Link	pending
0001654954-24-001969.txt	Edgar Link	pending
0001654954-24-001969-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vism-20231231.xsd	Edgar Link	pending
vism_10q.htm	Edgar Link	pending
vism_10qimg1.jpg	Edgar Link	pending
vism_ex311.htm	Edgar Link	pending
vism_ex312.htm	Edgar Link	pending
vism_ex321.htm	Edgar Link	pending
vism_ex322.htm	Edgar Link	pending
vism-20231231_def.xml	Edgar Link	unprocessable
vism-20231231_pre.xml	Edgar Link	unprocessable
vism_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
vism-20231231_cal.xml	Edgar Link	unprocessable
vism-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism

2024 Q1 Form 10-Q Financial Statement

#000165495424001969 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VISM VISIUM TECHNOLOGIES, INC. Stock $vism

2024 Q1 Form 10-Q Financial Statement

#000165495424001969 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VISM
VISIUM TECHNOLOGIES, INC. Stock $vism